Beyond Victoza: Novo Nordisk Sheds Light On GLP-1/Insulin Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Diabetes drug maker Novo Nordisk reports strong second quarter results based on its GLP-1 product, but could be facing some problems with other drugs in the pipeline.